198 related articles for article (PubMed ID: 21052545)
1. Targeted Therapy of Ewing's Sarcoma.
Subbiah V; Anderson P
Sarcoma; 2011; 2011():686985. PubMed ID: 21052545
[TBL] [Abstract][Full Text] [Related]
2. Identification of various exon combinations of the ews/fli1 translocation: an optimized RT-PCR method for paraffin embedded tissue -- a report by the CWS-study group.
Stegmaier S; Leuschner I; Aakcha-Rudel E; Münch P; Kazanowska B; Bekassy A; Treuner J; Koscielniak E
Klin Padiatr; 2004; 216(6):315-22. PubMed ID: 15565546
[TBL] [Abstract][Full Text] [Related]
3. FOXO1 is a direct target of EWS-Fli1 oncogenic fusion protein in Ewing's sarcoma cells.
Yang L; Hu HM; Zielinska-Kwiatkowska A; Chansky HA
Biochem Biophys Res Commun; 2010 Nov; 402(1):129-34. PubMed ID: 20933505
[TBL] [Abstract][Full Text] [Related]
4. Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor(WT1).
Subbiah V; Brown RE; Jiang Y; Buryanek J; Hayes-Jordan A; Kurzrock R; Anderson PM
PLoS One; 2013; 8(7):e68985. PubMed ID: 23922674
[TBL] [Abstract][Full Text] [Related]
5. Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma.
Lin PP; Brody RI; Hamelin AC; Bradner JE; Healey JH; Ladanyi M
Cancer Res; 1999 Apr; 59(7):1428-32. PubMed ID: 10197607
[TBL] [Abstract][Full Text] [Related]
6. Screening for DAX1/EWS-FLI1 functional inhibitors identified dihydroorotate dehydrogenase as a therapeutic target for Ewing's sarcoma.
Watanabe M; Kosaka H; Sugawara M; Maemoto M; Ono Y; Uemori T; Shizu R; Yoshinari K
Cancer Med; 2023 Apr; 12(8):9802-9814. PubMed ID: 36825574
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.
Rao DD; Jay C; Wang Z; Luo X; Kumar P; Eysenbach H; Ghisoli M; Senzer N; Nemunaitis J
Mol Ther; 2016 Aug; 24(8):1412-22. PubMed ID: 27166877
[TBL] [Abstract][Full Text] [Related]
8. Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma.
Ban J; Jug G; Mestdagh P; Schwentner R; Kauer M; Aryee DN; Schaefer KL; Nakatani F; Scotlandi K; Reiter M; Strunk D; Speleman F; Vandesompele J; Kovar H
Oncogene; 2011 May; 30(18):2173-80. PubMed ID: 21217773
[TBL] [Abstract][Full Text] [Related]
9. Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma.
Boro A; Prêtre K; Rechfeld F; Thalhammer V; Oesch S; Wachtel M; Schäfer BW; Niggli FK
Int J Cancer; 2012 Nov; 131(9):2153-64. PubMed ID: 22323082
[TBL] [Abstract][Full Text] [Related]
10. Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent.
Uren A; Toretsky JA
Future Oncol; 2005 Aug; 1(4):521-8. PubMed ID: 16556028
[TBL] [Abstract][Full Text] [Related]
11. Differentiating Ewing's sarcoma from other round blue cell tumors using a RT-PCR translocation panel on formalin-fixed paraffin-embedded tissues.
Lewis TB; Coffin CM; Bernard PS
Mod Pathol; 2007 Mar; 20(3):397-404. PubMed ID: 17334332
[TBL] [Abstract][Full Text] [Related]
12. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells.
Tanaka K; Iwakuma T; Harimaya K; Sato H; Iwamoto Y
J Clin Invest; 1997 Jan; 99(2):239-47. PubMed ID: 9005992
[TBL] [Abstract][Full Text] [Related]
13. A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis.
Leacock SW; Basse AN; Chandler GL; Kirk AM; Rakheja D; Amatruda JF
Dis Model Mech; 2012 Jan; 5(1):95-106. PubMed ID: 21979944
[TBL] [Abstract][Full Text] [Related]
14. High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition.
Awad O; Yustein JT; Shah P; Gul N; Katuri V; O'Neill A; Kong Y; Brown ML; Toretsky JA; Loeb DM
PLoS One; 2010 Nov; 5(11):e13943. PubMed ID: 21085683
[TBL] [Abstract][Full Text] [Related]
15. Junction region of EWS-FLI1 fusion protein has a dominant negative effect in Ewing's sarcoma in vitro.
Jully B; Vijayalakshmi R; Gopal G; Sabitha K; Rajkumar T
BMC Cancer; 2012 Nov; 12():513. PubMed ID: 23145994
[TBL] [Abstract][Full Text] [Related]
16. DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells.
García-Aragoncillo E; Carrillo J; Lalli E; Agra N; Gómez-López G; Pestaña A; Alonso J
Oncogene; 2008 Oct; 27(46):6034-43. PubMed ID: 18591936
[TBL] [Abstract][Full Text] [Related]
17. Ewing's sarcoma: overcoming the therapeutic plateau.
Subbiah V; Kurzrock R
Discov Med; 2012 Jun; 13(73):405-15. PubMed ID: 22742646
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma.
Erkizan HV; Uversky VN; Toretsky JA
Clin Cancer Res; 2010 Aug; 16(16):4077-83. PubMed ID: 20547696
[TBL] [Abstract][Full Text] [Related]
19. Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein.
Nakatani F; Tanaka K; Sakimura R; Matsumoto Y; Matsunobu T; Li X; Hanada M; Okada T; Iwamoto Y
J Biol Chem; 2003 Apr; 278(17):15105-15. PubMed ID: 12560328
[TBL] [Abstract][Full Text] [Related]
20. The dual inhibitory effect of thiostrepton on FoxM1 and EWS/FLI1 provides a novel therapeutic option for Ewing's sarcoma.
Sengupta A; Rahman M; Mateo-Lozano S; Tirado OM; Notario V
Int J Oncol; 2013 Sep; 43(3):803-12. PubMed ID: 23857410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
